FTC Filed Contempt Motion Against Martin Shkreli
The motion alleges that Shkreli violated a lifetime ban from the pharmaceutical industry.
Updated on Oct. 13, 2026 in Healthcare
Live Poll
Should courts have the authority to permanently ban individuals from working in an entire industry?
The Federal Trade Commission and seven states have petitioned a federal court to hold Martin Shkreli in contempt for allegedly violating a 2022 lifetime ban from the pharmaceutical industry. The filing follows claims that Shkreli traded pharmaceutical stocks and broadcasted management opinions.
Why it matters
The case tests the enforcement reach of a lifetime industry ban, a rare regulatory penalty intended to prevent recidivism in the pharmaceutical sector. For operators, it underscores the strict, long-term compliance mandates that can follow federal judgments involving anti-competitive conduct.
Seven states have joined the Federal Trade Commission in the motion for contempt filed in federal court. This action seeks to enforce a lifetime industry ban issued by the court in 2022 following findings of anti-competitive practices related to the drug Daraprim.
The players
Martin Shkreli
A former pharmaceutical executive who received a lifetime industry ban following anti-competitive findings.
Federal Trade Commission
The federal regulatory agency responsible for enforcing competition laws and protecting consumers in the U.S. market.
The details
The FTC alleges that Shkreli disregarded the 2022 court order by actively trading pharmaceutical stocks and publicly disseminating opinions on the management of companies in the sector. These actions purportedly violate the terms of his lifetime industry ban, which was originally imposed after he was found to have organized an anti-competitive scheme concerning the price and availability of Daraprim. The current motion asks the federal judge to determine the extent of these violations.
Timeline
2017: Martin Shkreli stood trial for securities fraud.
2022: The court issued a lifetime pharmaceutical industry ban.
May 2022: Shkreli was released from prison.
October 13, 2026: The FTC and seven states filed the contempt motion.
Market Landscape
This filing follows the 2022 lifetime pharmaceutical industry ban, a significant enforcement action aimed at curbing anti-competitive behavior. The motion signals a shift toward stricter, ongoing oversight of individuals barred from the sector by federal authorities.
Operators in highly regulated sectors should maintain clear records of how they monitor compliance with individual-level bans or industry sanctions. The potential for repeat litigation underscores the importance of adhering to the specific terms set out in judicial and agency orders.
The takeaway
This case illustrates that federal lifetime bans carry long-term monitoring risks that remain active well after an individual's prison release. Operators should ensure their internal compliance protocols are robust enough to distinguish between personal investment activity and potential regulatory violations.
Further reading
For broader trends in industry regulation, see Healthcare.
Live Poll
Should courts have the authority to permanently ban individuals from working in an entire industry?
